Healthcare ❯ Pharmaceuticals ❯ Drug Development ❯ GLP-1 Treatments
Metsera cited an FTC warning about Novo’s bid structure, positioning Pfizer’s higher-upfront, more certain offer for a mid-November shareholder vote.
